Table of Contents

company-logo

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Dividend Announcement

• Foghorn Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Foghorn Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Foghorn Therapeutics Dividend History

Foghorn Therapeutics Dividend Yield

Foghorn Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Foghorn Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Foghorn Therapeutics Financial Ratios

P/E ratio-5.42
PEG ratio1.06
P/B ratio-17.48
ROE167.93%
Payout ratio0.00%
Current ratio4.77
Quick ratio4.77
Cash Ratio1.02

Foghorn Therapeutics Dividend FAQ

Does Foghorn Therapeutics stock pay dividends?
Foghorn Therapeutics does not currently pay dividends to its shareholders.
Has Foghorn Therapeutics ever paid a dividend?
No, Foghorn Therapeutics has no a history of paying dividends to its shareholders. Foghorn Therapeutics is not known for its dividend payments.
Why doesn't Foghorn Therapeutics pay dividends?
There are several potential reasons why Foghorn Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Foghorn Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Foghorn Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Foghorn Therapeutics a dividend aristocrat?
Foghorn Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Foghorn Therapeutics a dividend king?
Foghorn Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Foghorn Therapeutics a dividend stock?
No, Foghorn Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Foghorn Therapeutics stocks?
To buy Foghorn Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Foghorn Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.